|1.||Alvarez-Mon, Melchor: 5 articles (07/2010 - 05/2002)|
|2.||Reyes, Eduardo: 3 articles (07/2010 - 03/2006)|
|3.||Pivel, J P: 3 articles (04/2003 - 10/2001)|
|4.||Guerrero, A: 3 articles (04/2003 - 10/2001)|
|5.||Brieva, A: 3 articles (04/2003 - 10/2001)|
|6.||Monserrat, Jorge: 2 articles (07/2010 - 06/2006)|
|7.||Miravitlles, Marc: 2 articles (05/2008 - 04/2005)|
|8.||Callol, Luis: 2 articles (05/2008 - 04/2005)|
|9.||Alvarez-Sala, José Luis: 2 articles (05/2008 - 03/2006)|
|10.||Morera, Josep: 2 articles (05/2008 - 04/2005)|
03/01/2003 - "[Pilot study of coadjuvant treatment of recurrent cystitis in women by means of AM3 (Immnoferon)]."
03/01/2003 - "The aim is to evaluate the effectiveness of AM3 (Inmunoferon) in the treatment of the recurrent cystitis in women in order to know the rate of good results, previously to design a clinical trial. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
09/01/2004 - "Systematic search of controlled clinical trials that used AM3 in some treatment group and that included data on the clinical effects of this drug on patients with COPD. "
05/17/2008 - "AM3 is an immunomodulator that significantly improves the quality of life of patients with chronic obstructive pulmonary disease (COPD). "
05/17/2008 - "[Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups]."
03/01/2006 - "PBMCs of COPD patients showed clear functional T-lymphocyte abnormalities that are rescued by AM3 treatment."
03/01/2006 - "Seventy COPD patients were randomized to receive either AM3 or a placebo orally for 90 consecutive days. "
09/01/2004 - "[Effect of immunomodulator AM3 on the exacerbations in patients with chronic bronchitis: a systematic review of controlled trials]."
02/01/1997 - "In middle-aged patients with chronic bronchitis (MACBpts) AM3 treatment resulted in significant increases in the number of monocytes as well as their phagocytic and chemotactic activity. "
02/01/1997 - "Of particular interest was the clinical effect of AM3 treatment in chronic bronchitis (CB) patients and various aged volunteers. "
07/01/2010 - "AM3 is a low-toxicity biological response modifier with regulatory effects on innate and adaptative immunity, and the ability to normalise the production of tumour necrosis factor alpha (TNFalpha). "
06/01/2006 - "Effects of AM3 (Inmunoferon) on increased serum concentrations of interleukin-6 and tumour necrosis factor receptors I and II in cyclists."
06/01/2006 - "We report the serum concentrations of interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-a), tumour necrosis factor receptors I and II (TNFR-I and -II) in a prospective, randomized, double-blind trial involving the administration of AM3 (Inmunoferon), an oral booster immunomodulator, or placebo to 16 professional cyclists (n = 8 in each group) for 65 consecutive days. "
|2.||Type I Tumor Necrosis Factor Receptors
|3.||Interleukin-6 (Interleukin 6)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Interleukin-12 (IL 12)
|7.||Messenger RNA (mRNA)
|9.||Hydroxyproline (4 Hydroxyproline)
|10.||Antiviral Agents (Antivirals)
|1.||Renal Dialysis (Hemodialysis)